Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies

Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.

Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee

The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.

News: Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain

News coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article

Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

View the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract

Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]